Fresh analysis indicates that people who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise programs.
Findings released in a prominent health publication shows that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such drugs should be aware of the risk of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about 18 months.
Comparing Therapies
The study, which looked at 37 of studies involving thousands of patients, compared the results of GLP-1 agonists with other pills.
Researchers note that people who lose weight through lifestyle changes alone usually experience a more gradual weight regain—around 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Doctors propose the way of the drugs explains the amplified rebound.
These medications copy a natural hormone called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines advise the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, considering the significant potential of relapse, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
Individuals who have discontinued the medication report a sudden resurgence of cravings.
"It was like something flipping and you become ravenous," described an individual.
This difficulty is compounded if individuals have not developed permanent dietary or behavioural changes during treatment.
Growing Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, experts emphasize that while these medications are powerful tools for shedding pounds, they are not a standalone cure and lasting health benefits hinges on combined behavioural support.
